Stockscreener 앱 받기
2.72
1.81%
-0.05
시장 영업 전:
2.74
0.02
+0.74%
전일 마감가:
$2.77
열려 있는:
$2.78
하루 거래량:
836.94K
Relative Volume:
1.05
시가총액:
$610.20M
수익:
$596.48M
순이익/손실:
$123.72M
주가수익비율:
4.9599
EPS:
0.5484
순현금흐름:
$106.59M
1주 성능:
-6.53%
1개월 성능:
-12.26%
6개월 성능:
-8.42%
1년 성능:
-8.72%
1일 변동 폭
$2.705
$2.81
1주일 범위
$2.705
$3.33
52주 변동 폭
$2.215
$5.28
큐어백 Stock (CVAC) Company Profile
CVAC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVAC
Curevac N V
|
2.72 | 610.20M | 596.48M | 123.72M | 106.59M | 0.5484 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
큐어백 Stock (CVAC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-06-08 | 개시 | SVB Securities | Outperform |
| 2023-01-19 | 업그레이드 | UBS | Neutral → Buy |
| 2023-01-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-01-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-18 | 개시 | JMP Securities | Mkt Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Hold |
| 2021-06-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-04-26 | 재개 | Credit Suisse | Underperform |
| 2021-04-26 | 개시 | Guggenheim | Neutral |
| 2020-12-10 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-09-08 | 개시 | Credit Suisse | Neutral |
| 2020-09-08 | 개시 | Jefferies | Hold |
모두보기
큐어백 주식(CVAC)의 최신 뉴스
CureVac (NASDAQ:CVAC) Stock Price Down 7.2%What's Next? - MarketBeat
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions (NASDAQ:CVAC) - Seeking Alpha
CureVac (CVAC) Stock Surges After Favorable Patent Ruling - Stocks Telegraph
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps - Benzinga
Lululemon, General Motors and Apple fall premarket; CureVac gains By Investing.com - Investing.com Canada
Lululemon, General Motors and Apple fall premarket; CureVac gains - Investing.com India
CureVac, gold miners, Rocket Lab - TradingView
CureVac Patent Validated in BioNTech Dispute, Infringement Hearing Set for July - Marketscreener.com
PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News - RTTNews
CureVac’s amended patent upheld by European Patent Office By Investing.com - Investing.com South Africa
European Patent Office declares CureVac mRNA patent valid - Marketscreener.com
CureVac up 13% as court upholds validity of patent in BioNTech spat - Seeking Alpha
CureVac’s amended patent upheld by European Patent Office - Investing.com
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Yahoo Finance
CureVac N.V. (CVAC) Gets Positive Validity Decision In Suit Vs BioNTech (BNTX)Bloomberg - StreetInsider
EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE - Sharewise
Amundi Sells 54,048 Shares of CureVac (NASDAQ:CVAC) - Defense World
CureVac Stock: Recovery Continues Despite Weekly Fluctuations - Sharewise
CureVac N.V.'s (NASDAQ:CVAC) largest shareholders are individual investors with 38% ownership, private equity firms own 31% - Yahoo Finance UK
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet - ACCESS Newswire
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board - ACCESS Newswire
CureVac: The mid-term effect of pipeline pruning -February 21, 2025 at 08:16 am EST - Marketscreener.com
Is CureVac N.V. (CVAC) the Best Get Rich Fast Stock to Buy Now? - Insider Monkey
12 Best Get Rich Fast Stocks To Buy Now - Insider Monkey
A History of Outperforming Analyst Forecasts and Beating the Odds: CureVac N.V (CVAC) - SETE News
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators - ACCESS Newswire
mRNA Pioneer CureVac Clinches Elite Innovation Status with 1,000-Patent Arsenal - StockTitan
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal year in vaccine race - MSN
CureVac Appoints Klaus Edvardsen as Chief Development Officer - ACCESS Newswire
JMP Securities Reiterates “Market Outperform” Rating for CureVac (NASDAQ:CVAC) - Defense World
CureVac (NASDAQ:CVAC) Shares Gap UpWhat's Next? - MarketBeat
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch (CORRECTED) - Benzinga
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch - Benzinga
CureVac (NASDAQ:CVAC) Trading Down 5.8%Time to Sell? - MarketBeat
Individual investors among CureVac N.V.'s (NASDAQ:CVAC) largest stockholders and were hit after last week's 6.1% price drop - Simply Wall St
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia - MSN
CureVac NV (FRA:5CV) Altman Z-Score : 3.43 (As of Feb. 01, 2025) - GuruFocus.com
CureVac NV (FRA:5CV) Momentum Rank : 7 (As of Feb. 01, 2025) - GuruFocus.com
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Sold by Ballentine Partners LLC - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update - ACCESS Newswire
Brokers Offer Predictions for CureVac FY2025 Earnings - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update - ACCESS Newswire
22,946 Shares in CureVac (NASDAQ:CVAC) Bought by Barclays PLC - Defense World
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - ACCESS Newswire
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer - ACCESS Newswire
FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs - MarketBeat
Companies Like CureVac (NASDAQ:CVAC) Are In A Position To Invest In Growth - Yahoo Finance
CureVac (NASDAQ:CVAC) Stock Price Down 3.7%What's Next? - MarketBeat
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
큐어백 (CVAC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.89%
0.13%
자본화:
|
볼륨(24시간):